Among them, inhibition of metabotropic glutamate receptor 5 (mGluR5) is most extensively studied as multiple mGluR5 antagonists have been shown to exhibit disease-modifying potential by causing a reduction in protein synthesis and correction in behavioral abnormalities in FXS animal models, such as Fmr1 KO mice. Here, GRM5 is linked to fragile X syndrome.